ALNYLAM PHARMACEUTICALS, INC. Loss Contingency Accrual
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Loss Contingency Accrual of $0 as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyAccrualAtCarryingValue · last filed 2026-07-30
- 2026-06-30: Loss Contingency Accrual $0.00.
- 2025-12-31: Loss Contingency Accrual $0.00.
- 2024-12-31: Loss Contingency Accrual $0.00.
- 2021-12-31: Loss Contingency Accrual $0.00.
| Period end | Loss Contingency Accrual |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 |
| 2025-12-31 | $0.00 10-Q · filed 2026-07-30 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-12 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2020-12-31 | $41.22M 10-K · filed 2022-02-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |